Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 13/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5521406 | 0.91 | NOS1 (0.44) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL3757239 | 0.91 | NOS1 (0.46) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL3758359 | 0.88 | NOS1 (0.44) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL3760847 | 0.88 | NOS1 (0.44) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL3760405 | 0.85 | NOS1 (0.39) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL4408579 | 0.84 | NOS1 (0.50) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL3756936 | 0.84 | NOS1 (0.55) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL3755577 | 0.83 | NOS1 (0.61) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL6063670 | 0.83 | NOS1 (0.46) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 | |
| SCHEMBL3764208 | 0.83 | PIK3CG (0.49) | NOS1PIK3CGPIK3CAPIK3CBHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663244-B1 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF TNF-ALPHA-RELATED DISEASES. | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | claimed |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | 4 AZA BIOSCIENCE NV (BE) | 2007-01-04 | — | — | US | claimed |
| US-7501513-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2009-03-10 | — | — | US | disclosed |
| US-7276506-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2007-10-02 | — | — | US | disclosed |
| EP-1663244-B1 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF TNF-ALPHA-RELATED DISEASES. | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | 4 AZA BIOSCIENCE NV (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20060287314-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2006-12-21 | — | — | US | disclosed |
| US-20060189620-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2006-08-24 | — | — | US | disclosed |
| EP-1663244-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-ALPHA-RELATED DISEASES. | 4 AZA Bioscience nv (BE) | 2006-06-07 | — | — | EP | disclosed |
| EP-1658081-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA Bioscience nv (BE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005025574-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. | 4 AZA BIOSCIENCE NV (BE) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005021003-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2005-03-10 | — | — | WO | disclosed |
| US-20040077859-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077859-A1 | Immunosuppressive effects of pteridine derivatives | TPMT, NFATC1, MALT1 | NOS1 141/4885PIK3CG 1880/4885PIK3CA 1012/4885 |
| US-20060287314-A1 | Immunosuppressive effects of pteridine derivatives | TPMT, NFATC1, MALT1 | NOS1 118/4885PIK3CG 1658/4885PIK3CA 1002/4885 |
| US-20060189620-A1 | Immunosuppressive effects of pteridine derivatives | TPMT, NFATC1, MALT1 | NOS1 141/4885PIK3CG 1880/4885PIK3CA 1012/4885 |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | TNF, TNFRSF1A, TLR4 | NOS1 47/4885PIK3CG 2581/4885PIK3CA 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.